Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: OXB
1 year chart More charts
digital-look imported chart image
Deal OXB Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Oxford Biomedica
www.oxfordbiomedica.co.uk
Deal Oxford Biomedica Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica's products use genes as the mediators of a...

Read more
Full Oxford Biomedica profile here
Pdf

Oxford Biomedica shares rise on positive review findings

August 08 2012, 9:31am The studies into RetinoStat and StarGen for the treatment of macular degeneration and Stargardt disease were reviewed by the Data Safety Monitoring Board (DSMB) - an independent panel of specialists

Shares in Oxford Biomedica (LON:OXB) were up three per cent this morning after it revealed positive review findings into clinical eye studies it is carrying out.

The studies into RetinoStat and StarGen for the treatment of macular degeneration and Stargardt disease were reviewed by the Data Safety Monitoring Board (DSMB) - an independent panel of specialists.

Both were designed and developed by the firm using its proprietary LentiVector gene delivery technology.

In the ongoing phase 1 RetinoStat study for "wet" age related macular degeneration, nine patients have been treated so far (of 18) at each of three dose levels and no serious "adverse events" related to RetinoStat or its administration were found. The DSMB gave support to proceed to the final patient cohort.

In the phase I/IIa clinical study of StarGen, eight patients have been treated so far (of up to 28) and DSMB support has been gained to proceed to the third patient cohort.

Chief executive John Dawson told investors: "The continued progress of our ophthalmology portfolio, supported by another positive DSMB review, is encouraging - particularly given that early RetinoStat data demonstrate sustained therapeutic protein expression in the eye following a single administration.

"The favourable safety profile of our novel ocular gene therapies further supports the wider LentiVector platform safety package with over 33 patients treated to date across the ocular and Parkinson's disease programmes."

Age-related macular degeneration (AMD) is a major cause of blindness affecting an estimated 25 to 30 million people worldwide. 

Stargardt disease is the most common juvenile degenerative retinal disease which affects approximately 80-100,000 patients in the US and Europe.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.